medcheck™ from dnalife

PATIENT INFORMATION
NAME: Sample Patient
DOB: 16/Feb/2000
SEX AT BIRTH: Female

SPECIMEN DETAILS
BARCODE: GNL-DL-00000
SAMPLE ID: 0000
TYPE: Copan FLOQSwab
COLLECTED: 02/Dec/2023

ORDERED BY
Nordic Laboratories
REPORT GENERATED: 07/May/2024

Summary of Genetic Lab Data & Phenotypes

Gene	Allele Result	Phenotype Result
CYP3A4	*1/*1	Normal Metabolizer
CYP2D6	*2/*4	Intermediate Metabolizer
CYP2C9	*2/*3	Poor Metabolizer
CYP2C19	*1/*1	Normal Metabolizer
SLCO1B1	*1/*1	Normal Function
CYP2B6	*1/*1	Normal Metabolizer
CYP3A5	*3/*3	Poor Metabolizer

This is a short summary of the full medication report. The patient's results are now accessible within the clinical decision support software, TreatGx and ReviewGx, and can be used with other clinical information to enable precision prescribing and medication management. The final genotype/phenotype call is at the discretion of the laboratory director. Medication changes should only be initiated at the discretion of the patient's healthcare provider after a full assessment.

Methods

DNA was extracted from dried blood spot (DBS) card by Chemagic 360 system (Revvity) and processed in a Biomark X platform (Standard Biotools) with Advanta™ Pharmacogenomics Assay.

Limitations

The annotations and interpretations provided in this report are based on scientific literature and do not take into account drug-drug interactions, medical conditions or other clinical factors that may affect medication response. Gene-drug interactions are ranked according to guidelines, level of evidence and clinical utility. GenXys reports and TreatGx Clinical Decision Support are regularly updated. Current predicted phenotype and allele functionality may change in the future depending on new evidence. Phenotype annotations for CYP2C9 are based on total activity scores as defined by CPIC[79]. Genetic test results and interpretation may be inaccurate for individuals who have undergone or are receiving non-autologous blood transfusion, tissue, or organ transplant therapies.

The report includes alleles of proteins involved in the metabolism of many medications. In rare cases, a variant that is not covered may be typed as *1 or other variants. In the case of pseudogenes and mutations in the untranslated regions of genes, incorrect allele typing may occur despite proper SNP detection. Preferential amplification of one allele over another present in the sample may also lead to incorrect genotyping.

Liability Disclaimer

This test was developed and its performance characteristics determined by GenXys Health Care Systems. It has not been cleared or approved by the US Food and Drug Administration. The report is not a diagnostic test, and TreatGx is not a prescribing system. You should discuss your pharmacogenetic information with a physician or other health care provider before you act upon the pharmacogenetic information resulting from this report. The medication brand names are not an exhaustive list and do not include combination therapies. Not all medications in this report are included in the TreatGx or ReviewGx software or other GenXys derivative works.



Dr Juha Matilainen, Laboratory Director, PhD

07/May/2024

Date of Signature

Nordic Laboratories Oy Laboratory Director: Dr Juha Matilainen | Elimäenkatu 15, 00510 Helsinki, Finland +358444918371 filabs@nordicgroup.eu

medcheck™ from dnalife

PATIENT INFORMATION

NAME: Sample Patient
DOB: 16/Feb/2000
SEX AT BIRTH: Female

SPECIMEN DETAILS

BARCODE: GNL-DL-00000
SAMPLE ID: 0000
TYPE: Copan FLOQSwab
COLLECTED: 02/Dec/2023

ORDERED BY

Nordic Laboratories
REPORT GENERATED: 07/May/2024

Nordic Laboratories Oy Laboratory Director: Dr Juha Matilainen | Elimäenkatu 15, 00510 Helsinki, Finland +358444918371 filabs@nordicgroup.eu

medcheck™ from dnalife

PATIENT INFORMATION
NAME: Sample Patient
DOB: 16/Feb/2000
SEX AT BIRTH: Female

SPECIMEN DETAILS
BARCODE: GNL-DL-00000
SAMPLE ID: 0000
TYPE: Copan FLOQSwab
COLLECTED: 02/Dec/2023

ORDERED BY
Nordic Laboratories
REPORT GENERATED: 07/May/2024

	1 Mild or no known interaction	2 Moderate gene-drug interaction: Consider alternative medications	2 Moderate gene-drug interaction: May require an increased dose	2 Moderate gene-drug interaction: May require a reduced dose	2 Moderate gene-drug interaction: May reduce efficacy	2 Moderate gene-drug interaction: May increase adverse events	3 Serious drug-gene interaction: evaluate and consider alternative medications
Analgesia	Alfentanil Carisoprodol Codeine Fentanyl Hydrocodone Morphine Tramadol Venlafaxine	Meloxicam Piroxicam Tenoxicam		Amitriptyline Celecoxib Desipramine Flurbiprofen Ibuprofen Imipramine Nortriptyline	Celecoxib Flurbiprofen Ibuprofen Meloxicam Piroxicam Tenoxicam	Amitriptyline Celecoxib Desipramine Flurbiprofen Ibuprofen Imipramine Meloxicam Nortriptyline Piroxicam Tenoxicam	
Autoimmune	Cyclosporine Tacrolimus			Siponimod		Siponimod	
Cancer	Erdafitinib	Tamoxifen	Tamoxifen		Tamoxifen		
Cardiovascular	Atorvastatin Carvedilol Clopidogrel Lovastatin Nebivolol Pitavastatin Pravastatin Propranolol		Warfarin	Flecainide Fluvastatin Warfarin	Flecainide Metoprolol Propafenone Warfarin	Flecainide Fluvastatin Metoprolol Propafenone Warfarin	

Nordic Laboratories Oy Laboratory Director: Dr Juha Matilainen | Elimäenkatu 15, 00510 Helsinki, Finland +358444918371 filabs@nordicgroup.eu

medcheck™ from dnalife

PATIENT INFORMATION
NAME: Sample Patient
DOB: 16/Feb/2000
SEX AT BIRTH: Female

SPECIMEN DETAILS
BARCODE: GNL-DL-00000
SAMPLE ID: 0000
TYPE: Copan FLOQSwab
COLLECTED: 02/Dec/2023

ORDERED BY
Nordic Laboratories
REPORT GENERATED: 07/May/2024

	1 Mild or no known interaction	2 Moderate gene-drug interaction: Consider alternative medications	2 Moderate gene-drug interaction: May require an increased dose	2 Moderate gene-drug interaction: May require a reduced dose	2 Moderate gene-drug interaction: May reduce efficacy	2 Moderate gene-drug interaction: May increase adverse events	3 Serious drug-gene interaction: evaluate and consider alternative medications
	Rosuvastatin Simvastatin						
Gastroenterology	Metoclopramide Ondansetron		Dexlansoprazole Lansoprazole Omeprazole Pantoprazole	Dronabinol Meclizine	Dronabinol Meclizine	Dronabinol Meclizine	
Infection	Efavirenz Voriconazole						
Mental Health	Amoxapine Amphetamine Aripiprazole lauroxil Atomoxetine Citalopram Clobazam Escitalopram Lofexidine Protriptyline Risperidone Sertraline Venlafaxine			Amitriptyline Clomipramine Desipramine Doxepin Imipramine Nortriptyline Paroxetine Trimipramine		Alprazolam Amitriptyline Aripiprazole Asenapine Brexpiprazole Bromazepam Cariprazine Chlordiazepoxide Chlorpromazine Clomipramine Clonazepam Clorazepate Clozapine Desipramine Diazepam	Zuclopenthixol

1	2					3
Mild or no known interaction	Moderate gene-drug interaction					Serious drug-gene interaction: evaluate and consider alternative medications
	Consider alternative medications	May require an increased dose	May require a reduced dose	May reduce efficacy	May increase adverse events	
					Doxepin	
					Flupentixol	
					Fluphenazine	
					Flurazepam	
					Fluvoxamine	
					Haloperidol	
					Iloperidone	
					Imipramine	
					Lorazepam	
					Loxapine	
					Lurasidone	
					Methotrimeprazine	
					Molindone	
					Nitrazepam	
					Nortriptyline	
					Olanzapine	
					Oxazepam	
					Paliperidone	
					Paroxetine	
					Perphenazine	
					Pimozide	
					Prochlorperazine	
					Promethazine	
					Quetiapine	
					Temazepam	
					Thioridazine	
					Triazolam	

	1 Mild or no known interaction	2 Moderate gene-drug interaction: Consider alternative medications	2 Moderate gene-drug interaction: May require an increased dose	2 Moderate gene-drug interaction: May require a reduced dose	2 Moderate gene-drug interaction: May reduce efficacy	2 Moderate gene-drug interaction: May increase adverse events	3 Serious drug-gene interaction: evaluate and consider alternative medications
						Trifluoperazine Trimipramine Vortioxetine Ziprasidone	
Neurology	Brivaracetam Clobazam Deutetrabenazine Donepezil Galantamine Propranolol Tetrabenazine Valbenazine Venlafaxine			Amitriptyline Desipramine Fosphenytoin Nortriptyline Phenytoin	Fosphenytoin Metoprolol Phenytoin	Amitriptyline Clonazepam Desipramine Diazepam Fosphenytoin Metoprolol Nortriptyline Phenytoin	
Other	Avatrombopag Cevimeline Elagolix Eltrombopag Flibanserin Oral contraceptives						Eliglustat
Rheumatology		Meloxicam Piroxicam Tenoxicam		Celecoxib Flurbiprofen Ibuprofen	Celecoxib Flurbiprofen Ibuprofen Meloxicam	Celecoxib Flurbiprofen Ibuprofen Meloxicam	

medcheck™ from dnalife

PATIENT INFORMATION
NAME: Sample Patient
DOB: 16/Feb/2000
SEX AT BIRTH: Female

SPECIMEN DETAILS
BARCODE: GNL-DL-00000
SAMPLE ID: 0000
TYPE: Copan FLOQSwab
COLLECTED: 02/Dec/2023

ORDERED BY
Nordic Laboratories
REPORT GENERATED: 07/May/2024

	1 Mild or no known interaction	2 Moderate gene-drug interaction: Consider alternative medications	2 May require an increased dose	2 May require a reduced dose	2 May reduce efficacy	2 May increase adverse events	3 Serious drug-gene interaction: evaluate and consider alternative medications
					Piroxicam Tenoxicam	Piroxicam Tenoxicam	
Urology	Darifenacin Fesoterodine Mirabegron Tamsulosin Tolterodine						

Nordic Laboratories Oy Laboratory Director: Dr Juha Matilainen | Elimäenkatu 15, 00510 Helsinki, Finland +358444918371 filabs@nordicgroup.eu